Local delivery of doxorubicin for malignant glioma by a biodegradable PLGA polymer sheet

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3317-3326

  Manome, Yoshinobu ^a   Kobayashi, Toshiaki ^b   Mori, Mariko ^a   Suzuki, Rie ^a   Funamizu, Naotake ^a   Akiyama, Nobutake ^a   Inoue, Sachiko ^c   Tabata, Yasuhiko ^c   Watanabe, Michiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Doxorubicin; Glioma; Local delivery; PLGA

Indexed keywords

CAMPTOTHECIN; CISPLATIN; CYSTATIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; HORMONE; IMMUNOTOXIN; INTERFERON; METHOTREXATE; OXALIPLATIN; PACLITAXEL; POLYGLACTIN; POLYMER; RADIOSENSITIZING AGENT; RETINOIC ACID; TUMOR ANTIGEN; USNIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABLE IMPLANT; BIODEGRADATION; BRAIN TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ELECTRON MICROSCOPY; GLIOBLASTOMA; IMPLANTABLE PORT SYSTEM; MOUSE; NONHUMAN; PHOTODYNAMICS; POLYMERIZATION; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOCOMPATIBLE MATERIALS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GLIOMA; LACTIC ACID; MICROSPHERES; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, INBRED F344;

EID: 33750695260     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Ohgaki H and Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489, 2005.
2. Barrie M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X, Hoang-Xuan K, Braguer D, Martin PM, Peragut JC, Grisoli F and Chinot O: Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 16: 1177-1184, 2005.
3. Cohen MH, Johnson JR and Pazdur R: Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11: 6767-6771, 2005.
4. Yoshii Y, Maki Y, Tsuboi K, Tomono Y, Nakagawa K and Hoshino T: Estimation of growth fraction with bromodeoxyuridine in human central nervous system tumors. J Neurosurg 65: 659-663, 1986.
5. Hamstra DA, Moffat BA, Hall DE, Young JM, Desmond TJ, Carter J, Pietronigro D, Frey KA, Rehemtulla A and Ross BD: Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor - a pharmacokinetic study. J Neurooncol 73: 225-238, 2005.
6. Yimam MA, Bui T and Ho RJ: Effects of lipid association on lomustine (CCNU) administered intracerebrally to syngeneic 36B-10 rat brain rumors. Cancer Lett, 2006.
7. Seong H, An TK, Khang G, Choi SU, Lee CO and Lee HB: BCNU-loaded poly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro. Int J Pharm 251: 1-12, 2003.
8. Lee JS, An TK, Chae GS, Jeong JK, Cho SH, Lee HB and Khang G: Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma. Eur J Pharm Biopharm 59: 169-175, 2005.
9. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J and Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 5: 79-88, 2003.
10. 6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11: 2747-2755, 2005.
11. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96: 766-776, 2006.
12. Manome Y, Watanabe M, Futaki K, Ishiguro H, Iwagami S, Noda K, Dobashi H, Ochiai Y, Ohara Y, Sanuki K, Kunieda T and Ohno T: Development of a syngenic brain-tumor model resistant to chloroethyl-nitrosourea using a methylguanine DNA methyltransferase cDNA. Anticancer Res 19: 5313-5318, 1999.
13. Manome Y, Yoshinaga H, Watanabe M and Ohno T: Adenoviral transfer of antisenses or ribozyme to O6-methylguanine-DNA methyltransferase mRNA in brain-tumor model resistant to chloroethyl-nitrosourea. Anticancer Res 22: 2029-2036, 2002.
14. Lesniak MS, Upadhyay U, Goodwin R, Tyler B and Brem H: Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 25: 3825-3831, 2005.
15. Webb AR, Yang J and Ameer GA: Biodegradable polyester elastomers in tissue engineering. Expert Opin Biol Ther 4: 801-812, 2004.
16. Fonseca C, Simoes S and Gaspar R: Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83: 273-286, 2002.
17. Kang BK, Chon SK, Kim SH, Jeong S, Kim MS, Cho SH, Lee HB and Khang G: Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int J Pharm 286: 147-156, 2004.
18. Mo Y and Lim LY: Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release 108: 244-262, 2005.
19. Mo Y and Lim LY: Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Release. 707: 30-42, 2005.
20. Sahoo SK and Labhasetwar V: Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2: 373-383, 2005.
21. Lin R, Shi Ng L and Wang CH: In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials 26: 4476-4485, 2005.
22. Yoo HS and Park TG: Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 70: 63-70, 2001.
23. Mallery SR, Pei P, Kang J, Ness GM, Ortiz R, Touhalisky JE and Schwendeman SP: Controlled-release of doxorubicin from poly(lactide-co- glycolide) microspheres significantly enhances cytotoxicity against cultured AIDS-related Kaposi's sarcoma cells. Anticancer Res 20: 2817-2825, 2000.
24. Inoue K, Onishi H, Kato Y, Michiura T, Nakai K, Sato M, Yamamichi K, Machida Y and Nakane Y: Comparison of intraperitoneal continuous infusion of floxuridine and bolus administration in a peritoneal gastric cancer xenograft model. Cancer Chemother Pharmacol 53: 415-422, 2004.
25. Cegnar M, Premzl A, Zavasnik-Bergant V, Kristl J and Kos J: Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp Cell Res 301: 223-231, 2004.
26. Tong W, Wang L and D'Souza MJ: Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin. Drug Dev Ind Pharm 29: 745-756, 2003.
27. 3H](6)-5-fluorouracil-loaded PLGA microspheres. Eur J Pharm Biopharm 53: 293-299, 2002.
28. Hagiwara A, Sakakura C, Shirasu M, Yamasaki J, Togawa T, Takahashi T, Muranishi S, Hyon S and Ikada Y: Therapeutic effects of 5-fluorouracil microspheres on peritoneal carcinomatosis induced by Colon 26 or B-16 melanoma in mice. Anticancer Drugs 9: 287-289, 1998.
29. Lagarce F, Cruaud O, Deuschel C, Bayssas M, Griffon-Etienne G and Benoit J: Oxaliplatin loaded PLAGA microspheres: design of specific release profiles. Int J Pharm 242: 243-246, 2002.
30. Singh UV and Udupa N: In vitro characterization of methotrexate loaded poly(lactic-co-glycolic) acid microspheres and antitumor efficacy in Sarcoma-180 mice bearing tumor. Pharm Acta Helv 72: 165-173, 1997.
31. Kumagai S, Sugiyama T, Nishida T, Ushijima K and Yakushiji M: Improvement of intraperitoneal chemotherapy for rat ovarian cancer using cisplatin-containing microspheres. Jpn J Cancer Res 87: 412-417, 1996.
32. Waeckerle-Men Y and Groettrup M: PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 57: 475-482, 2005.
33. Waeckerle-Men Y, Scandella E, Uetz-Von Allmen E, Ludewig B, Gillessen S, Merkle HP, Gander B and Groettrup M: Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co- glycolide) microspheres for immunotherapy. J Immunol Methods 287: 109-124, 2004.
34. McCarthy JR, Perez JM, Bruckner C and Weissleder R: Polymeric nanoparticle preparation that eradicates tumors. Nano Lett 5: 2552-2556, 2005.
35. Vargas A, Pegaz B, Debefve E, Konan-Kouakou Y, Lange N, Ballini JP, van den Bergh H, Gurny R and Delie F: Improved photodynamic activity of porphyrin loaded into nanopatticles: an in vivo evaluation using chick embryos. Int J Pharm 286: 131-145, 2004.
36. Konan YN, Berton M, Gurny R and Allemann E: Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur J Pharm Sci 18: 241-249, 2003.
37. Konan YN, Chevallier J, Gurny R and Allemann E: Encapsulation of p-THPP into nanoparticles: cellular uptake, subcellular localization and effect of serum on photodynamic activity. Photochem Photobiol 77: 638-644, 2003.
38. Geze A, Venier-Julienne MC, Saulnier P, Varlet P, Daumas-Duport C, Devauchelle P and Benoit JP: Modulated release of IdUrd from poly (D,L-lactide-co-glycolide) microspheres by addition of poly (D,L-lactide) oligomers. J Control Release 58: 311-322, 1999.
39. Reza MS and Whateley TL: Iodo-2'-deoxyuridine (IUdR) and 125IUdR loaded biodegradable microspheres for controlled delivery to the brain. J Microencapsul 15: 789-801, 1998.
40. Prabha S and Labhasetwar V: Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res 21: 354-364, 2004.
41. Jilek S, Ulrich M, Merkle HP and Walter E: Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells. Pharm Res 21: 1240-1247, 2004.
42. Panyam J, Zhou WZ, Prabha S, Sahoo SK and Labhasetwar V: Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J 16: 1217-1226, 2002.
43. Gill JS, Zhu X, Moore MJ, Lu L, Yaszemski MJ and Windebank AJ: Effects of NFkappaB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials 23: 2773-2781, 2002.
44. Benny O, Duvshani-Eshet M, Cargioli T, Bello L, Bikfalvi A, Carroll RS and Machluf M: Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth. Clin Cancer Res 11: 768-776, 2005.
45. Bandi N, Ayalasomayajula SP, Dhanda DS, Iwakawa J, Cheng PW and Kompella UB: Intratracheal budesonide-poty(lactide-coglycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol 57: 851-860, 2005.
46. Ribeiro-Costa RM, Alves AJ, Santos NP, Nascimento SC, Goncalves EC, Silva NH, Honda NK and Santos-Magalhaes NS: In vitro and in vivo properties of usnic acid encapsulated into PLGA-microspheres. J Microencapsul 21: 371-384, 2004.
47. Sanchez A, Tobio M, Gonzalez L, Fabra A and Alonso MJ: Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci 18: 221-229, 2003.
48. Ferdous AJ, Stembridge NY and Singh M: Role of monensin PLGA polymer nanoparticles and liposomes as potentiator of ricin A immunotoxins in vitro. J Control Release 50: 71-78, 1998.
49. Jeong YI, Song JG, Kang SS, Ryu HH, Lee YH, Choi C, Shin BA, Kim KK, Ahn KY and Jung S: Preparation of poly(DL-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid. Int J Pharm 259: 79-91, 2003.
50. Labrie F, Li S, Belanger A, Cote J, Merand Y and Lepage M: Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat. Breast Cancer Res Treat 26: 253-265, 1993.
51. Chae GS, Lee JS, Kim SH, Seo KS, Kim MS, Lee HB and Khang G: Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer. Int J Pharm 301: 6-14, 2005.
52. Rohr UD, Oberhoff C, Markmann S, Gerber B, Scheulen M and Schindler AE: The safety of synthetic paclitaxel by intralesional delivery with OncoGeltrade mark into skin breast cancer metastases: method and results of a clinical pilot trial. Arch Gynecol Obstet 1-7, 2005.
53. Fournier C, Hecquet B, Bouffard P, Vert M, Caty A, Vilain MO, Vanseymortier L, Merle S, Krikorian A, Lefebvre JL et al: Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors. Cancer Res 51: 5384-5391, 1991.
54. Jordan B, Pasquier Y and Schnider A: Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin. Spinal Cord 42: 371-373, 2004.
55. Arico M, Nespoli L, Porta F, Caselli D, Raiteri E and Burgio GR: Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration. Med Pediatr Oncol 18: 261-263, 1990.